CD30 CAR T cell treatment for hard-to-treat lymphomas
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 trial tests a new immune therapy made from your own immune cells (CAR T cells) for relapsed or refractory Hodgkin or non-Hodgkin lymphoma that has CD30 on the tumor. It aims to see if the treatment can shrink the lymphoma and find the safest dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Hodgkin or non-Hodgkin lymphoma that has come back or not responded to treatment
- Your tumor tests positive for CD30 (a lab test from a pathology lab is required)
- You must be able to donate your own T cells that have at least 15% CD30CAR after processing
- Your blood counts and organs must be strong enough (example: hemoglobin at least 7, good kidney and liver tests, and enough lung function)
- Your heart and breathing must be stable (oxygen on room air above 90% and no major heart rhythm problems)
- You must meet age and safety rules (no pregnancy or breastfeeding; birth control required if sexually active)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy for CD30-positive lymphomas. The cells are made from donated blood and are designed to find and attack your cancer.
This trial tests a lab-made immune cell therapy (CAR T) that targets CD30 on certain lymphoma cells. It may help people whose Hodgkin or non-Hodgkin lymphoma has come back or did not respond to usual treatments, including transplant and other medicines.
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
This trial tests a new treatment called LCAR-HL30 for people with Hodgkin's lymphoma or anaplastic large cell lymphoma that has come back or not responded to therapy. The treatment targets cells with a protein called CD30 to help your body fight the cancer.
This trial tests a new treatment made from your own immune cells, which are modified to find and attack CD30-positive lymphoma cells. It is for people with Hodgkin or non-Hodgkin lymphoma that has come back or not responded to other treatments.
This trial tests a new treatment using your own immune cells (T-cells) that are specially designed to attack a protein called CD30 found on Hodgkin lymphoma cells. It's given after a stem cell transplant to try to prevent the cancer from coming back in people with high-risk disease.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.